Abstract: A resin composition including: at least one resin ingredient selected from the group made of a resin (A) having a side chain (a) containing a hydrogen-bonding cross-linking moiety with a carbonyl-containing group and/or a nitrogen-containing heterocycle and having a glass transition point of 25° C. or lower, and a resin (B) containing a hydrogen-bonding cross-linking moiety and a covalent-bonding cross-linking moiety in a side chain and having a glass transition point of 25° C. or lower, wherein both the resin (A) and the resin (B) are a reaction product of a cross-linking agent with a maleic anhydride-modified thermoplastic resin having a melting point of 68° C. to 134° C. and a maleation rate of 0.5 to 2.5% by mass.

Abstract: A resin composition including: at least one resin ingredient selected from the group made of a resin (A) having a side chain (a) containing a hydrogen-bonding cross-linking moiety with a carbonyl-containing group and/or a nitrogen-containing heterocycle and having a glass transition point of 25° C. or lower, and a resin (B) containing a hydrogen-bonding cross-linking moiety and a covalent-bonding cross-linking moiety in a side chain and having a glass transition point of 25° C. or lower, wherein both the resin (A) and the resin (B) are a reaction product of a cross-linking agent with a maleic anhydride-modified thermoplastic resin having a melting point of 68° C. to 134° C. and a maleation rate of 0.5 to 2.5% by mass.

Abstract: A rubber composition includes: a rubber having no hydrogen-bond cross-linkable moiety; a specific polymer component; and a clay, wherein a content of the polymer component is 0.01 to 300 parts by mass relative to 100 parts by mass of the rubber, and an amount of the clay contained is 20 parts by mass or less relative to 100 parts by mass of the polymer component.

Abstract: Provided are a latent heat storage material that functions as a high-capacity heat storage material at a medium-to-low temperature region using a latent heat storage material composition including at least one kind of n-paraffin having 14 to 18 carbon atoms in a total amount of 100 parts by mass (hereinafter referred to as “n-paraffin-based latent heat storage material composition”) that contains, as a supercooling preventing agent, an n-alkyl alcohol and/or an n-alkyl amine having 20 to 24 carbon atoms (hereinafter referred to as “n-paraffin derivative”), and is obtained by the following a) step and b) step, a microcapsule heat storage material containing the latent heat storage material as a core material, and a method for producing the same. a) A step of melting and homogenizing the n-paraffin derivative and the n-paraffin-based latent heat storage material composition at a temperature range of 50 to 100° C.

Abstract: A paraffin-based latent heat storage material composition is provided which has a melting point close to the melting point of n-heptadecane and has a high latent heat of fusion. The paraffin-based latent heat storage material composition of the present invention substantially includes n-octadecane, and n-hexadecane and/or n-heptadecane. The paraffin-based latent heat storage material composition contains not less than 76% by mass of n-octadecane, not more than 23% by mass of n-hexadecane, and not more than 23% by mass of n-heptadecane (the total of the three is set to 100% by mass) and has a melting point lower than that of n-octadecane and latent heat of fusion of 210 J/g or more.

Abstract: A paraffin-based composition includes: n-eicosane, and at least one of n-octadecane and n-nonadecane. (1) the paraffin-based composition contains not less than 83% by mass of n-eicosane, not more than 13% by mass of n-octadecane, and not more than 17% by mass of n-nonadecane; (2) the paraffin-based composition has a melting point lower than a melting point of n-eicosane; and (3) the paraffin-based composition has latent heat of fusion of 230 J/g or more.

Abstract: The present invention provides a prophylactic or therapeutic agent, a pharmaceutical composition and a health-promoting food, which are used for human or other animal for the inhibition of the onset or progress of liver cancer, namely, an inhibitor of the onset or progress of liver cancer, which contains isoleucine, leucine and valine as active ingredients, wherein the weight ratio of isoleucine, leucine and valine is preferably 1:1.5 to 2.5:0.8 to 1.7 and the daily dose is 2.0 g to 50.0 g.

Abstract: In a microcapsule having a latent heat storage material having no vinyl group as a core material and a cross-linked polymer as a shell material, functions of the latent heat storage material is stably and efficiently expressed.

Abstract: The present invention provides a paraffin-based latent heat storage material composition that includes, as a main component, a mixture of n-hexadecane, n-pentadecane, and, optionally, n-tetradecane, in which 1) the mixture has the n-hexadecane content of 68 mass % or more, the n-pentadecane content of 1 mass % to 23 mass %, and the n-tetradecane content of 23 mass % or less, where the total sum of the n-hexadecane content, the n-pentadecane content, and the n-tetradecane content is 100 mass %, 2) the composition has a melting point lower than that of n-hexadecane, and 3) the composition has a latent heat of fusion of 200 J/g or more.

Abstract: The present invention provides compositions having, as active ingredients, a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

Abstract: The present application provides a method for the treatment of tumors where the lethal dose of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is increased to twice or more, the toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, gastrointestinal toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, hepatic toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, and/or cardiovascular toxicity at the pharmaceutically effective dosage of (Z)—N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide is reduced, by administering to a subject in need thereof a composition containing: (a) an effective amount of an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from t

Abstract: The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

Abstract: The present invention provides composition having as active ingredients a stilbene derivatively and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

Abstract: The present invention provides compositions having, as active ingredients, a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

Abstract: The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

Abstract: The present invention provides a prophylactic or therapeutic agent, a pharmaceutical composition and a health-promoting food, which are used for human or other animal for the inhibition of the onset or progress of liver cancer, namely, an inhibitor of the onset or progress of liver cancer, which contains isoleucine, leucine and valine as active ingredients, wherein the weight ratio of isoleucine, leucine and valine is preferably 1:1.5 to 2.5:0.8 to 1.7 and the daily dose is 2.0 g to 50.0 g.

Abstract: The present invention provides composition having as active ingredients a stilbene derivatively and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

Abstract: The present invention relates to an anti-tumor agent containing a tubulin polymerization-inhibitory active substance and an anti-inflammatory active substance. The present invention also relates to an anti-tumor pharmaceutical preparation containing one or more tubulin polymerization-inhibitory active substance and/or anti-inflammatory active substance, which can be individually combined with one or more additional tubulin polymerization-inhibitory active substance and/or anti-inflammatory active substance. The present invention also relates to methods and therapeutic regimens for administering the same to a subject in need thereof.

Abstract: The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.

Abstract: The present invention provides composition having as active ingredients a stilbene derivative and a platinum coordination compound which is highly efficacious and highly safe for treating tumors, particularly for the treatment of solid or malignant tumors and thus methods of cancer and tumor treatment using the composition are also provided.